Suppr超能文献

具有强大生物物理特性和生物活性的基于Fab的双特异性抗体形式。

Fab-based bispecific antibody formats with robust biophysical properties and biological activity.

作者信息

Wu Xiufeng, Sereno Arlene J, Huang Flora, Lewis Steven M, Lieu Ricky L, Weldon Caroline, Torres Carina, Fine Cody, Batt Micheal A, Fitchett Jonathan R, Glasebrook Andrew L, Kuhlman Brian, Demarest Stephen J

机构信息

a Eli Lilly Biotechnology Center ; San Diego , CA , USA.

出版信息

MAbs. 2015;7(3):470-82. doi: 10.1080/19420862.2015.1022694.

Abstract

A myriad of innovative bispecific antibody (BsAb) platforms have been reported. Most require significant protein engineering to be viable from a development and manufacturing perspective. Single-chain variable fragments (scFvs) and diabodies that consist only of antibody variable domains have been used as building blocks for making BsAbs for decades. The drawback with Fv-only moieties is that they lack the native-like interactions with CH1/CL domains that make antibody Fab regions stable and soluble. Here, we utilize a redesigned Fab interface to explore 2 novel Fab-based BsAbs platforms. The redesigned Fab interface designs limit heavy and light chain mixing when 2 Fabs are co-expressed simultaneously, thus allowing the use of 2 different Fabs within a BsAb construct without the requirement of one or more scFvs. We describe the stability and activity of a HER2×HER2 IgG-Fab BsAb, and compare its biophysical and activity properties with those of an IgG-scFv that utilizes the variable domains of the same parental antibodies. We also generated an EGFR × CD3 tandem Fab protein with a similar format to a tandem scFv (otherwise known as a bispecific T cell engager or BiTE). We show that the Fab-based BsAbs have superior biophysical properties compared to the scFv-based BsAbs. Additionally, the Fab-based BsAbs do not simply recapitulate the activity of their scFv counterparts, but are shown to possess unique biological activity.

摘要

已有大量创新的双特异性抗体(BsAb)平台被报道。从开发和生产角度来看,大多数平台都需要大量的蛋白质工程才能可行。单链可变片段(scFv)和仅由抗体可变域组成的双体已被用作制备BsAb的构建模块数十年。仅含Fv部分的缺点是它们缺乏与CH1/CL结构域的天然样相互作用,而这种相互作用能使抗体Fab区域稳定且可溶。在此,我们利用重新设计的Fab界面来探索2种新型基于Fab的BsAb平台。重新设计的Fab界面设计限制了2个Fab同时共表达时重链和轻链的混合,从而允许在一个BsAb构建体中使用2种不同的Fab,而无需一个或多个scFv。我们描述了一种HER2×HER2 IgG-Fab BsAb的稳定性和活性,并将其生物物理和活性特性与利用相同亲本抗体可变域的IgG-scFv进行比较。我们还生成了一种与串联scFv(也称为双特异性T细胞衔接器或BiTE)格式相似的EGFR × CD3串联Fab蛋白。我们表明,与基于scFv的BsAb相比,基于Fab的BsAb具有更优异的生物物理特性。此外,基于Fab的BsAb并非简单地重现其scFv对应物的活性,而是显示出具有独特的生物学活性。

相似文献

3
Nanocell targeting using engineered bispecific antibodies.
MAbs. 2015;7(1):53-65. doi: 10.4161/19420862.2014.985952.
4
Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Protein Eng Des Sel. 2010 Mar;23(3):115-27. doi: 10.1093/protein/gzp073. Epub 2009 Dec 18.
8
Computational design of a specific heavy chain/κ light chain interface for expressing fully IgG bispecific antibodies.
Protein Sci. 2017 Oct;26(10):2021-2038. doi: 10.1002/pro.3240. Epub 2017 Jul 31.
9
"BIClonals": Production of Bispecific Antibodies in IgG Format in Transiently Transfected Mammalian Cells.
Methods Mol Biol. 2019;1904:431-454. doi: 10.1007/978-1-4939-8958-4_22.
10
Influence of the bispecific antibody IgG subclass on T cell redirection.
MAbs. 2019 Aug/Sep;11(6):1012-1024. doi: 10.1080/19420862.2019.1624464. Epub 2019 Jun 26.

引用本文的文献

1
Trispecific eFab-eIg T-cell engagers targeting HER2 and HER3.
Front Immunol. 2025 Aug 27;16:1642454. doi: 10.3389/fimmu.2025.1642454. eCollection 2025.
3
Engineering a tumor-selective prodrug T-cell engager bispecific antibody for safer immunotherapy.
MAbs. 2024 Jan-Dec;16(1):2373325. doi: 10.1080/19420862.2024.2373325. Epub 2024 Jul 4.
4
Stepping forward: T-cell redirecting bispecific antibodies in cancer therapy.
Acta Pharm Sin B. 2024 Jun;14(6):2361-2377. doi: 10.1016/j.apsb.2024.03.027. Epub 2024 Mar 24.
5
Next generation of multispecific antibody engineering.
Antib Ther. 2023 Dec 8;7(1):37-52. doi: 10.1093/abt/tbad027. eCollection 2024 Jan.
6
Revolutionizing cancer immunotherapy: unleashing the potential of bispecific antibodies for targeted treatment.
Front Immunol. 2023 Dec 1;14:1291836. doi: 10.3389/fimmu.2023.1291836. eCollection 2023.
7
Bispecific antibodies in cancer therapy: Target selection and regulatory requirements.
Acta Pharm Sin B. 2023 Sep;13(9):3583-3597. doi: 10.1016/j.apsb.2023.05.023. Epub 2023 May 23.
8
Selection of High-Affinity Heterodimeric Antigen-Binding Fc Fragments from a Large Yeast Display Library.
Methods Mol Biol. 2023;2681:131-159. doi: 10.1007/978-1-0716-3279-6_9.
10
eIg-based bispecific T-cell engagers targeting EGFR: Format matters.
MAbs. 2023 Jan-Dec;15(1):2183540. doi: 10.1080/19420862.2023.2183540.

本文引用的文献

1
Improving target cell specificity using a novel monovalent bispecific IgG design.
MAbs. 2015;7(2):377-89. doi: 10.1080/19420862.2015.1007816.
5
Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
Cancer Res. 2014 Oct 1;74(19):5561-71. doi: 10.1158/0008-5472.CAN-13-3622-T. Epub 2014 Sep 16.
6
7
Generation of bispecific IgG antibodies by structure-based design of an orthogonal Fab interface.
Nat Biotechnol. 2014 Feb;32(2):191-8. doi: 10.1038/nbt.2797. Epub 2014 Jan 26.
9
A tale of two specificities: bispecific antibodies for therapeutic and diagnostic applications.
Trends Biotechnol. 2013 Nov;31(11):621-32. doi: 10.1016/j.tibtech.2013.08.007. Epub 2013 Oct 2.
10
Retargeting T cells for HER2-positive tumor killing by a bispecific Fv-Fc antibody.
PLoS One. 2013 Sep 23;8(9):e75589. doi: 10.1371/journal.pone.0075589. eCollection 2013.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验